Thus, low-dose trametinib combined with ritanserin, or with more selective DGKα inhibitors, is a novel anti-cancer combination therapy that could be developed to target human mammary cancers, as well as other human Ras-driven polarity-impaired cancers. This evidence concerns the gene DGKA and cancer.